| Systematic (IUPAC) name | |
|---|---|
| 6-[(4-chlorophenyl)(1,2,4-triazol-1-yl)methyl]- -1-methylbenzotriazole |
|
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Pharmacokinetic data | |
| Bioavailability | Very high |
| Metabolism | Hepatic |
| Half-life | 8 hours |
| Identifiers | |
| CAS number | 118949-22-7 |
| ATC code | L02BG05 |
| PubChem | CID 6918191 |
| ChemSpider | 5293402 |
| UNII | 1E2S9YXV2A |
| KEGG | D03786 |
| ChEMBL | CHEMBL224060 |
| Chemical data | |
| Formula | C16H13ClN6 |
| Mol. mass | 324.768 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
Vorozole is an imidazole based competitive inhibitor of the aromatase enzyme. It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane.
It is selective.[1]
Prous, J.; Grant, J.; Castaner, J.; Drugs Future 1994, 457.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||